Article
Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
Journal of gastroenterology and hepatology - 1 Oct 2006
Kazim Syed Naqui, Chauhan Ranjit, Das Bhudev Chandra, Sarin Shiv Kumar
Abstract excerpt
BACKGROUND AND AIM: Virologic breakthrough (VBTH) during long-term lamivudine therapy is believed to be due to the emergence of rtYM204I/VDD mutants. We observed VBTH in 17 of 67 patients receiving long-term lamivudine therapy. The YMDD mutant at the onset of VBTH and/or subsequently was seen in eight (47%) of 17 such patients. We investigated other potential loci in the viral genome contributing to VBTH....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.